Financial Contrast: Sunshine Biopharma (NASDAQ:SBFM) and ZyVersa Therapeutics (NASDAQ:ZVSA)

Sunshine Biopharma (NASDAQ:SBFM) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares Sunshine Biopharma and ZyVersa Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$24.09 million	0.16	-$4.51 million	($13.00)	-0.24
ZyVersa Therapeutics	N/A	N/A	-$98.30 million	N/A	N/A

Sunshine Biopharma has higher revenue and earnings than ZyVersa Therapeutics.

Profitability

This table compares Sunshine Biopharma and ZyVersa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-12.07%	-16.09%	-12.66%
ZyVersa Therapeutics	N/A	-172.50%	-90.88%

Risk and Volatility

Sunshine Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 14.7% of Sunshine Biopharma shares are owned by insiders. Comparatively, 0.7% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Sunshine Biopharma and ZyVersa Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	0	0	0	0	N/A
ZyVersa Therapeutics	0	0	1	0	3.00

ZyVersa Therapeutics has a consensus price target of $120.00, indicating a potential upside of 5,050.21%. Given ZyVersa Therapeutics’ higher probable upside, analysts plainly believe ZyVersa Therapeutics is more favorable than Sunshine Biopharma.

Summary

Sunshine Biopharma beats ZyVersa Therapeutics on 7 of the 10 factors compared between the two stocks.

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.